Shut up and follow the script!
Imagine a very small
Shut up and follow the script!
Imagine a very small biotech fighting openly with the FDA over their single life saving drug. The CEO was fired by the board. An established, respected CEO who had successfully dealt with the FDA in the past was brought in. The replacement CEO got the little biotech's first drug approved.
The little biotech was SRPT. Chris Garabedian was replaced by Ed Kaye and a little over a year later Etiplirsen received FDA approval. This all transpired between 2011 and 2016.
Does the first part of this comparison sound familiar?
NP has been replaced by the board for undocumented reasons. It is clear that everybody with CYDY has been directed to go silent. This helps control the shorts and shows everybody, especially the FDA, that CYDY is serious about its business. CYDY will hire an Ed Kaye type of CEO who has credibility with the FDA. CYDY is also getting the NASH, HIV BLA and Brazil results in shape to gain an approval.
Leronlimab is a seriously better new drug candidate than Etiplirsen was. LL studies are now designed to show that it is effective. Once these pending LL studies are polished and then presented to the FDA in a politically correct fashion by the new CEO, then CYDY will receive an approval. That is how SRPT played it and that is how CYDY is currently playing it.
The recent FDA letter of Feb means nothing. It'll only accentuate the political progress that CYDY has made when it receives LL approval
Don't expect to hear anything from CYDY until a new CEO has been hired.
Talk of a partnership or buy out will not get serious until CYDY has an approval. Big Pharma may be a pack of vicious, mean, bullying thugs but they are not stupid.
You can watch this story unfold, like it has for other biotechs, or you can pick up some more mighty inexpensive shares of CYDY now.
These are very frustrating but exciting times for CYDY longs. CYDY is now following a script that will work because LL works and because it is pretty obvious that the board and their "new friends" at SA have chartered out a known track to be successful, both scientifically and politically.
So don't get pissy because CYDY has gone silent. They have gone silent for some very good reasons. They'll talk when it is right and it will be different than before.
25
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...
Continue Reading
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...
Continue Reading
A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...
Continue Reading
Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...
Continue Reading
Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...
Continue Reading
A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...
Continue Reading
Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...
Continue Reading
Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...
Continue Reading
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
Top 5 Most Recently Viewed Articles
Critical One Energy Inc. Moves Forward with Howells Lake Acquisition Critical One Energy Inc. (formerly Madison Metals Inc.) has announced its latest strategic initiative: the acquisition of the Howells Lake Antimony Gold Project. This acquisition reflects the company's commitment to expanding its reach within the critical minerals sector, crucial for a sustainable...
Continue Reading
Breg, Inc. Announces Promotion of Steve Ingel to President Breg, Inc., a prominent provider of orthopedic bracing and support solutions, has made a significant announcement regarding its leadership. Steve Ingel has been elevated to the role of President, effective immediately. This change reflects the company's strategy to enhance its growth trajectory and fortify its...
Continue Reading
Schwarzkopf® Wins 2025 Product of the Year Award In an impressive recognition, Schwarzkopf® has won the 2025 Product of the Year USA Award for its innovative hair care line. The Schwarzkopf® Keratin Root Permanent Color and Keratin Root Temporary Color & Thickening Spray have emerged as champions in the Beauty category, voted for by 40,000 American shoppers. This...
Continue Reading
Symbotic Named to Fast Company’s Best Workplaces for Innovators Symbotic Inc. (Nasdaq: SYM), a pioneer in A.I.-enabled robotics for supply chains, has been ranked No. 58 on Fast Company’s sixth annual Best Workplaces for Innovators list. The honor celebrates organizations where new ideas are encouraged, supported, and moved into action—where innovation isn’t a...
Continue Reading
Pharmaceutical Water Market on the Rise The pharmaceutical water market is experiencing a robust increase, projected to surpass US$ 89.9 billion, driven by the escalating demand for high-purity water essential for drug manufacturing. Recent evaluations indicate that this sector, valued at approximately US$ 37.1 billion in the past years, is anticipated to expand at a...
Continue Reading